Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16769047 | 0.97 | KMT2A (0.38) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL9999753 | 0.90 | KMT2A (0.38) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL9999751 | 0.86 | KMT2A (0.40) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL16769030 | 0.85 | HPGD (0.46) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL17040412 | 0.84 | KMT2A (0.39) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL14062700 | 0.84 | HTT (0.34) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL16769029 | 0.82 | HPGD (0.46) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL14062763 | 0.82 | HTT (0.35) | KMT2AHTTL3MBTL1MEN1RAB9A | |
| SCHEMBL18069641 | 0.81 | KMT2A (0.40) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL21609892 | 0.81 | HPGD (0.47) | KMT2AHTTSMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | CTNND1, YWHAZ, DVL1 | KMT2A 4004/4885HTT 4050/4885SMN1; SMN2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.